There are three reasons that make HER2 a valid candidate for targeted therapy: (1) Its low expression levels in normal tissues, (2) Its overexpression in a significant part of human tumors, and (3) The critical role that its overexpression appears to play in the biological development of cancer cells. The gene discussed is ERBB2; the disease is cancer.